Lymphoma

Jim Kochenderfer, M.D., lends insight to the future of CAR T-cell therapy for hematologic malignancies.

How the side effects of radiation therapy almost killed me, and kept me from eating turkey.

Keytruda (pembrolizumab) was approved for the treatment of refractory or relapsed Hodgkin lymphoma.

Teaching the patient and caregiver reportable signs and symptoms and when to call the doctor cannot only save their line, but, more importantly, can save their life.” — WENDY A. NUNEZ , R.N.

Leo I. Gordon, M.D., discusses an exciting new trial for patients with non-Hodgkin lymphoma.

Just one person can make a difference for patients with blood cancer.

A recent phase 3 study showed that Imbruvica plus ublituximab may be a promising option for some patients with CLL.

Sometimes a cat isn't your problem, it's actually lymphoma.

CAR T-cell therapy is drastically changing the landscape of cancer treatment.

A friend at the chemotherapy clinic told his story, but never said a word.

Patient education and coordination from the care team are two vital aspects in delivering successful CAR T therapy.

Axicabtagene ciloleucel had high response rates in patients with non-Hodgkin lymphoma in a phase 2 study.

Getting dates while getting Adriamycin.

Your methods of coping with cancer might not always be sexy.

One quirky trick to cut down on hair loss from chemo made me detest refrigerators for life!

Please, If I could just complain, I mean explain, this whole after-treatment thing.

A bone marrow transplant story that even chemobrain won't let me forget.

Axicabtagene ciloleucel can lead to complete remission for patients with refractory diffuse large B-cell lymphoma, according to a recent study.

Car T-Cell therapy is being explored in multiple approaches to treat hematologic malignancies.

Cancer is really difficult, but if you look hard enough, you might find the perks.

Surviving cancer sometimes means re-imagining the life you dreamed about but never thought you would have.

Group exercise programs are beneficial to survivors of cancer, and can offer motivation from peers to continue living a healthy lifestyle.

John P. Leonard, M.D. spoke with CURE about some upcoming advancements in the treatment of follicular lymphoma.

Adding Ibrance to Imbruvica may be a promising treatment strategy for patients with mantle cell lymphoma, according to a recent study.

A recent study examined if the benefit from the drug brentuximab vedotin was worth the neuropathy that it causes for many patients with lymphoma.

Imbruvica was granted an accelerated FDA approval to treat some patients with marginal zone lymphoma (MZL).

Imbruvica (ibrutinib) improved survival for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL), according to study results that were recently presented.

Andrew D. Zelenetz, M.D., Ph.D. weighs in on recent research and the future of treating hematologic malignancies.

Stem cell transplant is still the only curative treatment option for many hematologic malignancies, even as novel drugs continue to emerge.